tiprankstipranks

SciSparc collaboration leads to publication of patient on binge behavior

SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines. The patent refers to SciSparc’s innovative combination therapy of N-Acylethanolamines and Clearmind’s MEAI, addressing binge behaviour, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue